Impact of a phone follow-up program on persistence with teriparatide or PTH(1-84) treatment.

Détails

ID Serval
serval:BIB_F5712C6A5314
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Impact of a phone follow-up program on persistence with teriparatide or PTH(1-84) treatment.
Périodique
Calcified tissue international
Auteur(s)
Tamone C., Fonte G., Panico A., Molinatti P.A., D'Amelio P., Isaia G.C.
ISSN
1432-0827 (Electronic)
ISSN-L
0171-967X
Statut éditorial
Publié
Date de publication
04/2012
Peer-reviewed
Oui
Volume
90
Numéro
4
Pages
272-278
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
A follow-up program to help patients suffering from severe osteoporosis during their therapy with teriparatide or PTH(1-84) has been designed and performed. The objective of this study was to evaluate the 18-month persistence on these therapies in patients participating in the program. We enrolled 382 patients who started teriparatide or PTH(1-84) following this program and compared them with a historical cohort of 398 patients treated with the same therapies but who did not participate in any follow-up program. At the beginning of the therapy, nurses trained patients on self-injection. Patients received one phone call per week during the first month, then one phone call per month and per 3 months during the following 5 and 12 months, respectively. In every call, nurses helped patients to resolve any possible issues and collected adverse event information. The persistence rate of the group following the program was 85.6%, 8.2% higher than that of the group not following any program (77.4%). The log-rank test on persistence rates on therapy in patients enrolled and not enrolled in the program was performed; the difference was statistically significant (P = 0.006). Discontinuation in the follow-up program group occurred mainly at early stages of the treatment due to adverse events. Our results show that patients suffering from severe osteoporosis treated with teriparatide or PTH(1-84) and enrolled in a follow-up program have higher persistence rates than patients not following the program.
Mots-clé
Aged, Bone Density, Bone Density Conservation Agents/administration & dosage, Bone Density Conservation Agents/therapeutic use, Female, Follow-Up Studies, Humans, Male, Parathyroid Hormone/administration & dosage, Parathyroid Hormone/therapeutic use, Telephone, Teriparatide/administration & dosage, Teriparatide/therapeutic use
Pubmed
Web of science
Création de la notice
16/01/2020 15:21
Dernière modification de la notice
17/01/2020 7:26
Données d'usage